论文部分内容阅读
慢性粒细胞性白血病(chronic myeloid leukemia,CML)是起源于骨髓造血干细胞克隆性增殖的恶性肿瘤。酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI)的出现,给CML的治疗带来了革命性变化,使CML患者生存率和生存时间极大延长。然而,TKI疗效并非总尽如人意,有些患者出现不能耐受,有些患者出现耐药,尤其出现ABL激酶T315I突变患者,目前国内常用的伊马替尼、尼洛替
Chronic myeloid leukemia (CML) is a malignant tumor that originates from the clonal proliferation of myeloid hematopoietic stem cells. The emergence of tyrosine kinase inhibitors (TKIs) has brought revolutionary changes in the treatment of CML, which greatly prolongs the survival rate and survival time of CML patients. However, the efficacy of TKI is not always satisfactory. Some patients are intolerant and some patients develop resistance. In particular, patients with ABL kinase T315I mutation are currently used in China. Imatinib,